Ping-tang recipe improves insulin resistance and attenuates hepatic steatosis in high-fat diet-induced obese rats

Chinese Journal of Integrative Medicine

Volumn 18, Issue 4, 2012, Pages 262-268

  Yang, Shu Yu ^a,b,c   Zhao, Neng Jiang ^b,c   Li, Xue Jun ^b,c   Zhang, Hui Jie ^b,c   Chen, Ke Ji ^a   Li, Can Dong ^a  

^a FUJIAN UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^b THE FIRST AFFILIATED HOSPITAL OF XIAMEN UNIVERSITY   (China)

^c Xiamen Diabetes Institute   (China)

Author keywords

AMP activated protein kinase; Insulin resistance; Non alcoholic fatty liver disease; Ping tang Recipe

Indexed keywords

ACETYL COENZYME A CARBOXYLASE; CHINESE DRUG; FATTY ACID BINDING PROTEIN; FATTY ACID SYNTHASE; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INSULIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; PING TANG; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; UNCLASSIFIED DRUG;

ABDOMINAL OBESITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD CHEMISTRY; CHINESE MEDICINE; CONTROLLED STUDY; DOWN REGULATION; DRUG SYNTHESIS; GLUCOSE METABOLISM; IMMUNOHISTOCHEMISTRY; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTRAABDOMINAL FAT; LIPID DIET; LIPOGENESIS; LIPOLYSIS; MALE; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR UPREGULATION; THERAPY EFFECT; TREATMENT DURATION; WESTERN BLOTTING;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; BODY WEIGHT; DIET, HIGH-FAT; DRUGS, CHINESE HERBAL; FATTY LIVER; GENE EXPRESSION REGULATION; GLUCOSE; GLUCOSE TOLERANCE TEST; INSULIN RESISTANCE; INTRA-ABDOMINAL FAT; LIPOGENESIS; LIPOLYSIS; LIVER; MALE; OBESITY; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; TRIGLYCERIDES;

EID: 84862736174     PISSN: 16720415     EISSN: 19930402     Source Type: Journal    
DOI: 10.1007/s11655-012-1023-0     Document Type: Article

References (20)

1. Chitturi S, Wong VW, Farrell G. Nonalcoholic fatty liver in Asia: firmly entrenched and rapidly gaining ground. J Gastroenterol Hepatol 2011;26(Suppl):163-172.
2. Alper AT, Hasdemir H, Sahin S, Ontürk E, Akyol A, Nurkalem Z, et al. The relationship between nonalcoholic fatty liver disease and the severity of coronary artery disease in patients with metabolic syndrome. Turk Kardiyol Dern Ars 2008;36:376-381.
3. Sanyal AJ. AGA technical review on nonalcoholic fatty liver disease. Gastroenterology 2002;123:1705-1725. (Pubitemid 35231670)
4. Ratziu V, Caldwell S, Neuschwander-Tetri BA. Therapeutic trials in nonalcoholic steatohepatitis: insulin sensitizers and related methodological issues. Hepatology 2010;52:2206-2215.
5. Tsochatzis EA, Papatheodoridis GV. Is there any progress in the treatment of non-alcoholic fatty liver disease? World J Gastrointest Pharmacol Ther 2011;2;1-5.
6. Zhang HX, Yang SY, Cao HX. Effect of Pingtang Recipe containing drug-serum on INS-1 pancreatic beta cells lipoapoptosis. Chin J Integr Tradit West Med (Chin) 2010;30;978-981.
7. Li XJ, Yang SY. Clinical observation on treatment of diabetes mellitus type 2 by Pingtang concentrated capsule. Chin J Integr Tradit West Med (Chin) 2002;22:854-855.
8. Lee MS, Kim D, Jo K, Hwang JK. Nordihydroguaiaretic acid protects against high-fat diet-induced fatty liver by activating AMP-activated protein kinase in obese mice. Biochem Biophys Res Commun 2010;401:92-97.
9. Ha SK, Chae C. Inducible nitric oxide distribution in the fatty liver of a mouse with high fat diet-induced obesity. Exp Anim 2010;59:595-604.
10. Kucera O, Garnol T, Lotková H, Staňková P, Mazurová Y, Hroch M, et al. The effect of rat strain, diet composition and feeding period on the development of a nutritional model of non-alcoholic fatty liver disease in rats. Physiol Res 2011;60;317-328.
11. Orlik B, Handzlik G, Olszanecka-Glinianowicz M. The role of adipokines and insulin resistance in the pathogenesis of nonalcoholic fatty liver disease. Postepy Hig Med Dosw 2010;64;212-219.
12. Qin Y, Tian YP. Preventive effects of chronic exogenous growth hormone levels on diet-induced hepatic steatosis in rats. Lipids Health Dis 2010;9;78.
13. Matsumoto M, Ogawa W, Akimoto K, Inoue H, Miyake K, Furukawa K, et al. PKClambda in liver mediates insulininduced SREBP-1c expression and determines both hepatic lipid content and overall insulin sensitivity. J Clin Invest 2003;112;935-944. (Pubitemid 38063751)
14. Cao H, Maeda K, Gorgun CZ, Kim HJ, Park SY, Shulman GI, et al. Regulation of metabolic responses by adipocyte/macrophage fatty acid-binding proteins in leptin-deficient mice. Diabetes 2006;55;1915-1922. (Pubitemid 44509962)
15. Liang H, Ward WF. PGC-1alpha, a key regulator of energy metabolism. Adv Physiol Educ 2006;30;145-151. (Pubitemid 44749372)
16. Gruzman A, Babai G, Sasson S. Adenosine monophosphate-activated protein kinase (AMPK) as a new target for antidiabetic drugs: a review on metabolic, pharmacological and chemical considerations. Rev Diabet Study 2009;6:13-36.
17. Barroso E, Rodríguez-Calvo R, Serrano-Marco L, Astudillo AM, Balsinde J, Palomer X, et al. The PPARβ/δ activator GW501516 prevents the down-regulation of AMPK caused by a high-fat diet in liver and amplifies the PGC-1α-lipin 1-PPARα pathway leading to increased fatty acid oxidation. Endocrinology 2011;152:1848-1859.
18. Yuan HD, Yuan HY, Chung SH, Jin GZ, Piao GC. An active part of Artemisia sacrorum Ledeb. attenuates hepatic lipid accumulation through activating AMP-activated protein kinase in human HepG2 cells. Biosci Biotechnol Biochem 2010;74;322-328.
19. Canto C, Auwerx J. PGC-1alpha, SIRT1 and AMPK, an energy sensing network that controls energy expenditure. Curr Opin Lipidol 2009;20;98-105.
20. Zhang BB, Zhou G, Li C. AMPK: an emerging drug target for diabetes and the metabolic syndrome. Cell Metab 2009;9;407-416.